Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. and Cullinan Therapeutics, Inc. will present results from the planned interim analysis of the Phase 3 REZILIENT3 study of investigational zipalertinib plus chemotherapy at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer in Seoul. The presentation has secured a place in Presidential Symposium 2 on September 14, giving the first detailed look at a pivotal trial that the companies disclosed on August 12 had already met its primary endpoint of progression-free survival in previously untreated, locally advanced or metastatic nonsquamous non-small cell lung cancer with EGFR exon 20 insertion mutations.
That distinction matters because the August 19 announcement is not new confirmation that REZILIENT3 succeeded. The clinically important news is that the data behind that positive topline finding are about to become visible. The companies have so far said the zipalertinib-containing regimen produced a statistically significant and clinically meaningful improvement in progression-free survival and that observed safety was manageable, but they have not disclosed the hazard ratio, median progression-free survival, response rates, duration of response, intracranial outcomes or detailed adverse-event profile. Those numbers will determine whether the Phase 3 success looks merely registrationally useful or sufficiently differentiated to alter a first-line treatment landscape that already contains an approved targeted combination.
REZILIENT3 enrolled 285 adults and compared zipalertinib plus platinum-based chemotherapy with chemotherapy alone. The global, randomized, controlled and open-label Phase 3 study included patients who had not previously received systemic treatment for locally advanced or metastatic disease, making it a direct test of whether adding the oral EGFR inhibitor to a conventional pemetrexed and platinum backbone can delay disease progression at the beginning of advanced-disease treatment rather than after other therapies fail. ClinicalTrials.gov lists the study as active but no longer recruiting, with progression-free survival assessed by blinded independent central review among its primary outcome measures.
Why does the September REZILIENT3 presentation matter more than the presidential symposium label itself?
A presidential symposium slot gives the study visibility, but conference prestige does not substitute for the underlying evidence. The central questions on September 14 will be how large the progression-free survival advantage actually was, how consistently the benefit appeared across clinically relevant subgroups, whether the combination produced an acceptable incremental toxicity burden and how mature the survival data were when the interim analysis triggered unblinding.
The Independent Data Monitoring Committee recommended that REZILIENT3 be unblinded after the planned interim analysis met the progression-free survival endpoint. That is an encouraging development for the program because the primary efficacy objective was reached before the study’s originally estimated completion, but the eventual significance depends heavily on the magnitude rather than the existence of statistical significance. A modest hazard-ratio improvement and a large one can both cross a statistical threshold while presenting very different clinical and commercial propositions.
Overall survival will also attract attention even if the dataset remains immature. REZILIENT3 permits patients assigned to chemotherapy to receive zipalertinib monotherapy after blinded independent central review confirms progression, according to the registered trial design. Such crossover can be clinically appropriate while complicating longer-term interpretation of overall survival differences between the original randomized groups.
The companies have said the trial will continue to monitor efficacy and safety. That means the September dataset should be viewed as pivotal interim evidence rather than the final word on durability, survival and longer-term tolerability.
How high is the competitive bar for zipalertinib in first-line EGFR exon 20 insertion NSCLC?
REZILIENT3 is entering a substantially different treatment environment from the one that existed when chemotherapy was the dominant first-line option for EGFR exon 20 insertion-positive advanced lung cancer.
The United States Food and Drug Administration approved amivantamab-vmjw with carboplatin and pemetrexed in March 2024 for first-line treatment of locally advanced or metastatic non-small cell lung cancer carrying EGFR exon 20 insertion mutations. That decision followed the Phase 3 PAPILLON study, in which median progression-free survival was 11.4 months with amivantamab plus chemotherapy compared with 6.7 months for chemotherapy alone, corresponding to a hazard ratio of 0.40.
Those figures create an unavoidable reference point when the zipalertinib data arrive, but they cannot be used as a head-to-head benchmark. REZILIENT3 and PAPILLON are separate studies conducted at different times with potentially different patient characteristics, assessment schedules, crossover rules and other design features. A numerically higher or lower median progression-free survival in REZILIENT3 would therefore not establish superiority or inferiority to amivantamab.
What REZILIENT3 can establish is whether adding zipalertinib to chemotherapy produces a sufficiently strong benefit over its own randomized chemotherapy control to support regulatory review and a credible place in the first-line discussion.
There is also a modality distinction. Zipalertinib is an orally available irreversible EGFR inhibitor designed to inhibit EGFR variants containing exon 20 insertions while limiting inhibition of wild-type EGFR. Amivantamab is an antibody-based therapy. The practical relevance of that difference, however, should not be overstated because the Phase 3 zipalertinib strategy still combines the oral targeted agent with chemotherapy rather than eliminating infused cytotoxic treatment.
What will the REZILIENT3 safety data need to show for an oral EGFR inhibitor added to chemotherapy?
Safety may become one of the most consequential parts of the September presentation because first-line treatment can continue for prolonged periods and patients may remain on components of therapy after the initial platinum cycles.
Earlier zipalertinib evidence offers some guidance but cannot replace first-line combination data. In the Phase 1/2 REZILIENT1 study involving previously treated EGFR exon 20 insertion-positive NSCLC, 244 patients received zipalertinib at the reported dose evaluated in the publication. Among 176 patients in the primary efficacy population, the confirmed objective response rate was 35.2% and median duration of response was 8.8 months. The most common Grade 3 or higher treatment-related adverse events included anemia at 7%, pneumonitis and rash at 2.5% each, with diarrhea, increased alanine aminotransferase and decreased platelet count each reported at 2%.
Those results helped establish the clinical rationale for the molecule, but REZILIENT3 asks a different question because zipalertinib is being layered onto pemetrexed and platinum chemotherapy in untreated patients. The conference presentation therefore needs to clarify treatment discontinuations, dose interruptions and reductions, hematologic toxicity, rash, diarrhea, pneumonitis or interstitial lung disease, and any treatment-related deaths or other serious adverse events.
A positive progression-free survival result can support a benefit-risk case only when the improvement is considered alongside the additional toxicity required to achieve it. That calculation becomes especially important in a market where clinicians already have a targeted first-line combination available.
How does the Phase 3 success interact with zipalertinib’s separate FDA review in previously treated patients?
Zipalertinib now has two regulatory narratives moving in parallel, and they should not be confused.
The drug remains investigational and has not been approved by any health authority. However, the United States Food and Drug Administration has already accepted a New Drug Application covering a different setting, specifically patients with locally advanced or metastatic EGFR exon 20 insertion-positive non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy, with or without previous amivantamab. The Prescription Drug User Fee Act target action date for that application is February 27, 2027.
That application is based on REZILIENT1 rather than REZILIENT3. In the pivotal Phase 2b evidence supporting the submission, the confirmed objective response rate in the primary efficacy population was about 35%, with median duration of response of 8.8 months. Among patients previously treated with platinum chemotherapy but not an exon 20-targeted therapy, the reported response rate was 40%.
The first-line Phase 3 result potentially broadens the program well beyond that initial regulatory opportunity. Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics said after the positive interim analysis that they intended to discuss the results with the Food and Drug Administration and pursue United States regulatory approval for zipalertinib plus chemotherapy in the first-line setting.
A successful second-line review would therefore not automatically authorize first-line use, while a positive REZILIENT3 trial does not itself constitute regulatory approval. Each indication requires its own evidence and regulatory determination.
Why is REZILIENT3 commercially important for Cullinan Therapeutics beyond clinical validation?
The first-line opportunity also has unusually direct economics for Cullinan Therapeutics.
Cullinan reported in its second-quarter update that it could receive $30 million upon United States regulatory approval in the later-line setting and up to $100 million upon a United States first-line approval. The company also has a 50/50 United States profit share under its zipalertinib collaboration structure. As of June 30, Cullinan reported approximately $356 million in cash, cash equivalents, investments and interest receivable and said its existing resources were expected to fund operations into 2029 under its current plan.
That means REZILIENT3 is not simply an externally partnered program producing an isolated milestone payment. If the combination eventually reaches the United States first-line market, its commercial performance could have a continuing financial impact on Cullinan.
For Taiho Oncology and Taiho Pharmaceutical, the program could add another targeted lung cancer asset to a broader oncology operation and extend zipalertinib across treatment lines if both regulatory strategies succeed.
Commercial potential still depends on considerably more than approval. Physicians would need to decide how the efficacy, toxicity and administration profile compares with available treatment strategies, while molecular testing must reliably identify the relatively uncommon EGFR exon 20 insertion population. Access, payer coverage, treatment sequencing and eventual guideline positioning would then influence actual uptake.
Could the REZILIENT3 dataset change how zipalertinib is positioned against other exon 20 therapies?
The EGFR exon 20 insertion market is no longer defined by a single targeted therapy. The Food and Drug Administration granted accelerated approval to the oral EGFR inhibitor sunvozertinib in July 2025 for patients whose disease had progressed on or after platinum-based chemotherapy, adding another targeted option in the later-line setting.
That evolution makes development sequence important. A therapy that enters later-line treatment first but subsequently generates convincing randomized first-line evidence can potentially move earlier in the treatment pathway, while the availability of multiple targeted agents increases pressure to establish a clear role based on efficacy, safety, central nervous system activity, administration and sequencing.
Zipalertinib has already demonstrated activity in previously treated patients, including patients with prior amivantamab exposure and patients with brain metastases, although subgroup findings from REZILIENT1 should remain distinct from the randomized first-line evidence. The Phase 3 presentation can materially strengthen the program if it demonstrates that the PFS benefit is broad and accompanied by a tolerability profile that clinicians consider workable in combination with chemotherapy.
Intracranial outcomes may be particularly informative. The REZILIENT3 registry includes intracranial response and duration measures among secondary outcomes, reflecting the importance of central nervous system disease in advanced lung cancer. Whether sufficiently mature intracranial data will be presented at WCLC has not yet been disclosed.
What are the numbers to watch when REZILIENT3 is presented on September 14?
The headline statistic will probably be the progression-free survival hazard ratio, because it will quantify how much adding zipalertinib reduced the risk of disease progression or death relative to chemotherapy within REZILIENT3. Median progression-free survival in both arms will then provide a more intuitive measure of the absolute time difference observed in the study.
Response rate and duration of response will help determine whether the PFS benefit reflects deeper and more durable tumor control, while subgroup analyses may indicate whether benefit was consistent across mutation variants, geographic groups, patients with central nervous system disease and other clinically relevant categories. Overall survival maturity and the impact of crossover will require careful interpretation.
The safety tables could be equally decisive. Detailed rates of Grade 3 or higher adverse events, serious adverse events, pneumonitis, treatment discontinuation and dose modification will show what patients had to tolerate in exchange for the improvement in disease control.
Until those data are presented, the strongest conclusion supported by the evidence is narrower than the conference announcement might initially suggest. REZILIENT3 has already crossed its prespecified progression-free survival threshold at a planned interim analysis, which meaningfully advances zipalertinib’s first-line program. What remains unresolved is whether the magnitude and quality of that benefit are sufficient to make the regimen clinically competitive in a setting where amivantamab plus chemotherapy has already established a randomized Phase 3 benchmark.
That answer should become substantially clearer at 8 a.m. Korea Standard Time on September 14, when Daniel Tan Shao Weng is scheduled to present the REZILIENT3 results during the IASLC World Conference on Lung Cancer Presidential Symposium in Seoul.
